01—Abstract
Summary
Summary of the 8-K filed July 8, 2024. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. entered into a Third Amendment and Incremental Facility Amendment to its Credit Agreement dated as of March 28, 2019, on July 2, 2024.
The amendment, with Bank of America, N.A. as administrative agent, established a new $130.0 milliona incremental term loan (the "New Term Loan"). The New Term Loan was fully drawn at closing and matures on July 2, 2027, with the entire principal due at maturity and no scheduled amortization before then. The company used the New Term Loan proceeds, together with cash on hand, to repay an outstanding term loan under the existing credit agreement of approximately $80 million and approximately $53 million of its 3.82% Series B Senior Notes due July 5, 2024.
The filing describes the refinancing as a way to retire that existing term debt and the maturing notes, but it does not state the resulting total debt balance or other effects on the company's leverage. The New Term Loan bears interest at term SOFR or a base rate, at the company's option, plus a margin tied to its net leverage ratio. The SOFR margin ranges from 1.250%b to 1.625%, the base rate margin from 0.250% to 0.625%, and term SOFR loans carry a 10 basis point credit spread adjustment.
At closing, the company elected 3-month term SOFR plus a 1.250%c margin. The loan includes customary mandatory and optional prepayment provisions, representations, affirmative and negative covenants, and events of default that would allow the agent to accelerate the full amount outstanding.
02—Key points
Key Highlights
- New $130.0 million incremental term loan, fully drawn at closing on July 2, 2024
- New Term Loan matures July 2, 2027, with the full principal due at maturity and no scheduled amortization
- Proceeds, plus cash on hand, used to repay an outstanding term loan of approximately $80 million
- Approximately $53 million of 3.82% Series B Senior Notes due July 5, 2024 repaid
- Initial interest rate set at 3-month term SOFR plus a 1.250% margin, with the margin tied to the net leverage ratio
- Margin range of 1.250% to 1.625% for SOFR loans and 0.250% to 0.625% for base rate loans, plus a 10 basis point credit spread adjustment on term SOFR
- Loan contains customary covenants and events of default, and the administrative agent may accelerate all amounts outstanding under the Amended Credit Agreement
03—Questions
Frequently Asked Questions
How much new debt did West Pharmaceutical take on, and when does it come due?
The company established a $130.0 million incremental term loan that was fully drawn at closing on July 2, 2024. It matures on July 2, 2027, and the entire stated principal is due at maturity with no scheduled amortization before then.
What was the new borrowing used for?
Together with cash on hand, the proceeds were used to repay an outstanding term loan under the existing credit agreement of approximately $80 million and approximately $53 million of 3.82% Series B Senior Notes due July 5, 2024.
What interest rate applies to the New Term Loan?
Interest accrues at term SOFR or a base rate, at the company's option, plus a margin that depends on the net leverage ratio. SOFR margins range from 1.250% to 1.625%, base rate margins from 0.250% to 0.625%, and term SOFR loans carry a 10 basis point credit spread adjustment. At closing, the company elected 3-month term SOFR plus 1.250%.
Can the lenders demand early repayment?
Yes. Upon an event of default, the administrative agent may take certain actions, including declaring the entire amount outstanding under the Amended Credit Agreement, including the New Term Loan, due and payable. The loan also has mandatory prepayment requirements for certain asset sales, dispositions, and non-permitted debt issuances.
Where can investors find the full terms of the amendment?
The Third Amendment and Incremental Facility Amendment, dated as of July 2, 2024, is filed as Exhibit 10.1 to the Current Report on Form 8-K and is incorporated by reference. The filing states that the summary in the 8-K is qualified in its entirety by that exhibit.
04—Continue